Oral drugs may protect cancer patients from blood clots
London, May 13: Taking oral drugs daily can be an effective treatment for nearly 10 million cancer patients worldwide suffering from a deadly blood clot condition, results from a clinical trial have showed.
People with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) -- either a blood clot in a deep vein or a condition in which one or more arteries in the lungs become blocked by a blood clot.
The results from the clinical trial called "select-d" suggested that prescribing the oral drug rivaroxaban significantly reduced VTE recurrence among patients with cancer.
"Clinicians were already adopting the oral drug into practice for non-cancer patients and now they have data from this study to indicate that this form of treatment is an alternative option for many cancer patients who have a clot," said lead author Annie Young, Professor at University of Warwick in the Britain.
Although there are many causes and risk factors for VTE, cancer patients are particularly at risk due to a combination of factors such as immobility, pancreatic and gastric tumours as well as chemotherapy, the researcher said.
For the "select-d" trial, researchers enrolled 406 patients who had cancer and VTE; most (69 per cent) were receiving cancer treatment (typically chemotherapy) at the time of their VTE.
Half were randomly assigned to receive low-molecular-weight heparin (dalteparin) and half were given the oral drug rivaroxaban. After six months of treatment, the VTE recurrence rate was four per cent among those taking the tablet and 11 per cent in those receiving dalteparin.
The results for secondary outcomes were mixed, the researcher said.
In patients receiving rivaroxaban, there were around the same percentage of major bleeding events (6 per cent) as those receiving dalteparin (4 per cent) but a marked and significant increase in clinically relevant non-major bleeds (13 per cent) with rivaroxaban compared to those having low molecular weight heparin (4 per cent).
The reason for increased bleeding is not known. It may be because rivaroxaban is more 'potent', the paper published in the Journal of Clinical Oncology said.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Allahabad HC orders probe into 'reinstatement' of teacher in UP's Barabanki
Lucknow (PTI): The Lucknow Bench of the Allahabad High Court on Friday ordered a probe by the special task force (STF) into alleged irregularities in the rejoining of a teacher at City Intermediate College in Barabanki, observing that the reinstatement appeared to be prima facie illegal.
The court also directed the recovery of the salary paid to the teacher during the disputed period.
A bench of Justice Rajeev Singh passed the order on a petition filed by the college management committee. The court expressed doubts over the roles of the District Inspector of Schools (DIOS), Barabanki, the college principal and the teacher concerned and hence, directed a detailed inquiry into the matter.
Taking note of alleged manipulation of records and misleading submissions, the court ordered the immediate transfer of the Barabanki DIOS to ensure a fair probe. It also directed the initiation of disciplinary proceedings against the then joint director of education of the Ayodhya division.
In its order, the court found that the teacher, Abhay Kumar, was initially appointed as an assistant teacher in 2018 but joined an Eklavya Model Residential School in Chhattisgarh as a lecturer in June 2024 without obtaining permission from the management. His subsequent request to retain the lien was rejected.
Despite this, he was allowed to rejoin the Barabanki College in September 2025 on the directions of the joint director of education and the DIOS, and was even paid the salary for October 2025. The court termed the rejoining "wholly illegal" and lacking any legal basis.
The bench also expressed concern over lapses in communication within the education department and directed the Uttar Pradesh chief secretary to ensure that official orders are communicated through email and WhatsApp as well, to prevent disputes.
The matter is next listed for hearing on May 28 when a compliance report is sought.
